According to the EMA and the FDA, common adverse events (occurring in 1 out of 10 people receiving the drug) associated with cefepime-enmetazobactam are high levels of transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] and bilirubin, diarrhea, headache, skin rash, and phlebitis at the injection site [5,6]. This evidence concerns the gene GPT and exanthem.